CASI Pharmaceuticals Company Profile (NASDAQ:CASI)

About CASI Pharmaceuticals

CASI Pharmaceuticals logoCASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CASI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.41
  • 50 Day Moving Average: $1.31
  • 200 Day Moving Average: $1.28
  • 52-Week Range: $0.78 - $1.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.88
  • P/E Growth: 0.00
  • Market Cap: $84.88M
  • Outstanding Shares: 60,196,000
  • Beta: 0.76
Profitability:
  • Return on Equity: -137.98%
  • Return on Assets: -52.97%
Debt:
  • Current Ratio: 9.58%
  • Quick Ratio: 9.58%
Additional Links:
Companies Related to CASI Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CASI Pharmaceuticals (NASDAQ:CASI) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (183.69% upside)

Analysts' Ratings History for CASI Pharmaceuticals (NASDAQ:CASI)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017Maxim GroupSet Price TargetBuy$4.00View Rating Details
11/16/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q3 2016($0.08)($0.03)ViewN/AView Earnings Details
8/15/2016Q2($0.04)($0.08)ViewN/AView Earnings Details
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
3/28/2016Q415($0.03)($0.05)ViewN/AView Earnings Details
11/13/2015Q315($0.07)($0.05)ViewN/AView Earnings Details
8/14/2015Q215($0.06)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.07)ViewN/AView Earnings Details
8/14/2014Q214($0.06)ViewN/AView Earnings Details
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details
3/21/2014Q413($0.05)$0.67 millionViewN/AView Earnings Details
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.02)$1.93 million$0.67 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CASI Pharmaceuticals (NASDAQ:CASI)
Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CASI Pharmaceuticals (NASDAQ:CASI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CASI Pharmaceuticals (NASDAQ:CASI)
Insider Ownership Percentage: 13.01%
Institutional Ownership Percentage: 3.62%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016Spectrum Pharmaceuticals IncMajor ShareholderBuy1,789,062$0.01$17,890.62View SEC Filing  
10/3/2016Wei-Wu HeDirectorBuy1,871,605$1.19$2,227,209.95View SEC Filing  
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.00View SEC Filing  
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CASI Pharmaceuticals (NASDAQ:CASI)
DateHeadline
News IconRecent Study: Metastatic Breast Cancer - Pipeline Review, H2 2016 (NASDAQ:CASI)
www.digitaljournal.com - February 14 at 4:53 PM
sbwire.com logoMultiple Sclerosis - Pipeline Review, H2 2016: New Research Report Available at Fast Market Research (NASDAQ:CASI)
www.sbwire.com - February 10 at 3:46 PM
bloomberg.com logoKen Keyong Ren M.D., Ph.D. (NASDAQ:CASI)
www.bloomberg.com - January 5 at 9:33 PM
marketexclusive.com logoCASI PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:CASI)
marketexclusive.com - December 20 at 9:42 PM
reuters.com logoBRIEF-Casi Pharmaceuticals Inc entered into amendment with Talon Therapeutics (NASDAQ:CASI)
www.reuters.com - December 17 at 9:20 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:CASI)
biz.yahoo.com - December 16 at 9:34 PM
us.rd.yahoo.com logo7:25 am CASI Pharma announces that China's FDA has accepted for review the Company's import drug registration application for EVOMELA for Injection (NASDAQ:CASI)
us.rd.yahoo.com - December 5 at 4:56 PM
streetinsider.com logoCASI Pharma's (CASI) Registration App for EVOMELA Accepted by China's FDA (NASDAQ:CASI)
www.streetinsider.com - December 5 at 12:30 PM
capitalcube.com logoCASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 (NASDAQ:CASI)
www.capitalcube.com - December 5 at 12:30 PM
News IconCASI Pharma Reports Third Quarter 2016 Financial Results (NASDAQ:CASI)
www.biospace.com - November 15 at 4:20 PM
reuters.com logoBRIEF-Casi Pharmaceuticals reports third quarter 2016 results (NASDAQ:CASI)
www.reuters.com - November 15 at 4:20 PM
4-traders.com logoCASI PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:CASI)
www.4-traders.com - November 15 at 4:20 PM
finance.yahoo.com logoCASI Pharmaceuticals Reports Third Quarter 2016 Financial Results (NASDAQ:CASI)
finance.yahoo.com - November 15 at 4:20 PM
finance.yahoo.com logoPhagelux announces the addition of Dr. Rong Chen as Global CMO (NASDAQ:CASI)
finance.yahoo.com - November 3 at 1:43 PM
4-traders.com logoBUYINS.NET: CASI SqueezeTrigger Price is $1.43. There is $163,306 That Short Sellers Still Need To Cover. (NASDAQ:CASI)
www.4-traders.com - November 1 at 4:08 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit (NASDAQ:CASI)
biz.yahoo.com - October 25 at 9:20 PM
4-traders.com logoBUYINS.NET: CASI SqueezeTrigger Price is $1.43. There is $168,050 That Short Sellers Still Need To Cover. (NASDAQ:CASI)
www.4-traders.com - October 18 at 4:01 PM
4-traders.com logoBUYINS.NET: CASI SqueezeTrigger Price is $1.43. There is $166,324 That Short Sellers Still Need To Cover. (NASDAQ:CASI)
www.4-traders.com - October 14 at 3:59 PM
marketexclusive.com logoCASI Pharmaceuticals Inc (NASDAQ:CASI) Files An 8-K (NASDAQ:CASI)
marketexclusive.com - October 7 at 4:01 PM
finance.yahoo.com logoCoverage initiated on CASI Pharma by Maxim Group (NASDAQ:CASI)
finance.yahoo.com - September 22 at 9:44 AM
News IconJapan Radio Co., Ltd. (6751) - Financial and Strategic SWOT Analysis Review - New Study Released (NASDAQ:CASI)
reports.pr-inside.com - September 15 at 11:58 AM
reuters.com logoBRIEF-Casi Pharmaceuticals Q2 loss per share $0.08 (NASDAQ:CASI)
www.reuters.com - August 16 at 10:35 AM
streetinsider.com logoCASI Pharma (CASI) Reports ENMD-2076 Phase 2 Met Stage 1 Endpoint in FLC (NASDAQ:CASI)
www.streetinsider.com - August 16 at 10:35 AM
finance.yahoo.com logo7:01 am CASI Pharma announces that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC (NASDAQ:CASI)
finance.yahoo.com - August 16 at 10:35 AM
publicnow.com logoCASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma (NASDAQ:CASI)
www.publicnow.com - August 16 at 10:35 AM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:CASI)
biz.yahoo.com - August 15 at 11:19 AM
publicnow.com logoCASI Pharmaceuticals Reports Second Quarter 2016 Financial Results (NASDAQ:CASI)
www.publicnow.com - August 15 at 11:19 AM
News IconRecent research into the metastatic breast cancer - pipeline review, H1 2016 just published (NASDAQ:CASI)
www.whatech.com - July 8 at 4:04 PM
finance.yahoo.com logoGlobal Metastatic Breast Cancer Pipeline Report 2016 - Pipeline Review of 128 Companies & Drug Profiles - Research and Markets (NASDAQ:CASI)
finance.yahoo.com - July 8 at 4:04 PM
News IconSupervisors discuss jail population (NASDAQ:CASI)
qctimes.com - July 1 at 9:14 PM
News IconMcAlester Man Facing Manslaughter Charge After Tulsa Crash (NASDAQ:CASI)
www.news9.com - July 1 at 9:14 PM
News IconPuerto Rico impone moratoria a deuda de casi 2.000 millones (NASDAQ:CASI)
www.oaoa.com - July 1 at 9:14 PM
News IconBartlesville Boy Learns He's Cancer-Free In Viral Video (NASDAQ:CASI)
www.newson6.com - July 1 at 9:14 PM
streetinsider.com logoForm 4 CASI Pharmaceuticals, For: Jun 24 Filed by: Shong Hugo (NASDAQ:CASI)
www.streetinsider.com - July 1 at 9:14 PM
News IconEmergency app Casi targets Gauteng (NASDAQ:CASI)
mybroadband.co.za - July 1 at 9:14 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities (NASDAQ:CASI)
biz.yahoo.com - June 27 at 4:47 PM
News IconTop 10 Orange is the New Black moments (NASDAQ:CASI)
newsinfilm.com - June 18 at 8:42 AM
finance.yahoo.com logoCASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO (NASDAQ:CASI)
finance.yahoo.com - June 13 at 11:18 AM
publicnow.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 (NASDAQ:CASI)
www.publicnow.com - June 12 at 11:29 PM
biz.yahoo.com logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a (NASDAQ:CASI)
biz.yahoo.com - June 3 at 4:47 PM
publicnow.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Cle (NASDAQ:CASI)
www.publicnow.com - June 1 at 7:13 AM
finance.yahoo.com logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) (NASDAQ:CASI)
finance.yahoo.com - June 1 at 7:00 AM
realistinvestor.com logoAnalysts Set 1-Year Price Target Of $3.75 On CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock - RealistInvestor.com (NASDAQ:CASI)
www.realistinvestor.com - May 29 at 7:30 PM
investornewswire.com logoCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Impact Score At 0 - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - May 29 at 10:52 AM
investornewswire.com logoHold Calls Count For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) At 0 - Investor Newswire (NASDAQ:CASI)
www.investornewswire.com - May 28 at 7:33 PM
finance.yahoo.com logoCASI PHARMACEUTICALS, INC. Financials (NASDAQ:CASI)
finance.yahoo.com - May 21 at 1:04 PM
prnewswire.com logoCASI Pharmaceuticals Reports First Quarter 2016 Financial Results - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - May 13 at 7:54 PM
4-traders.com logoCASI PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K) (NASDAQ:CASI)
www.4-traders.com - May 13 at 7:54 PM
publicnow.com logoCASI Pharmaceuticals Reports First Quarter 2016 Financial Results (NASDAQ:CASI)
www.publicnow.com - May 13 at 7:18 AM
prnewswire.com logoCASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For ... - PR Newswire (press release) (NASDAQ:CASI)
www.prnewswire.com - May 12 at 8:02 PM

Social

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Where is CASI Pharmaceuticals' stock going? Where will CASI Pharmaceuticals' stock price be in 2017?

2 analysts have issued twelve-month price targets for CASI Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $4.00 in the next twelve months.

When will CASI Pharmaceuticals announce their earnings?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

Who owns CASI Pharmaceuticals stock?

CASI Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.21%). Company insiders that own CASI Pharmaceuticals stock include Byte Ltd Sparkle, China Growth Fund Idg-Accel II, Cynthia W Hu, Ken Ren, Spectrum Pharmaceuticals Inc and Wei-Wu He.

Who bought CASI Pharmaceuticals stock? Who is buying CASI Pharmaceuticals stock?

CASI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Byte Ltd Sparkle, China Growth Fund Idg-Accel II, Cynthia W Hu, Ken Ren, Spectrum Pharmaceuticals Inc and Wei-Wu He.

How do I buy CASI Pharmaceuticals stock?

Shares of CASI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CASI Pharmaceuticals stock cost?

One share of CASI Pharmaceuticals stock can currently be purchased for approximately $1.41.

CASI Pharmaceuticals (NASDAQ:CASI) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Earnings History Chart

Earnings by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Dividend History Chart

Dividend Payments by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Last Updated on 2/24/2017 by MarketBeat.com Staff